Evaxion’s Personalized Melanoma Vaccine Maintains Responses Through Year Three, Stock Climbs

Evaxion stock up on durable three-year EVX-01 results in melanoma. Immune hit rate reached 89%, but only 6 patients continued on monotherapy.